Clinically, cervical precancerous lesion is one of the important diseases that endanger the life safety and fertility of young women. Women with histopathologically confirmed CIN2 need regular HPV, cervical cytology, and colposcopic biopsy if necessary to assess the outcome and progression of the disease. In this study, we intend to visit Fujian Maternal and Child Health Hospital, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science \& Technology and other hospitals, including 300 CIN2 participants aged 45 and below diagnosed by histopathology, and collect the remaining cervical secretions and cervical exfoliated cell samples after clinical examination, even if you do not participate in this clinical study. In clinical diagnosis, treatment and follow-up, it is also necessary to collect the above specimens for relevant medical tests. Therefore, it is of great clinical and scientific significance to explore the role of HPV integrated detection in predicting the prognosis of young women with CIN2.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Cervical histopathology testing at baseline
Timeframe: Baseline
Cervical histopathology testing at 6-month follow-up
Timeframe: 6-month follow-up
Cervical histopathology testing at 12-month follow-up
Timeframe: 12-month follow-up
Human Papillomavirus (HPV) viral integration test at baseline
Timeframe: Baseline
Human Papillomavirus (HPV) viral integration test at 6-month follow-up
Timeframe: 6-month follow-up
Human Papillomavirus (HPV) viral integration test at 12-month follow-up
Timeframe: 12-month follow-up
Cervical cytology testing at baseline
Timeframe: Baseline
Cervical cytology testing at 3-month follow-up
Timeframe: 3-month follow-up
Cervical cytology testing at 6-month follow-up
Timeframe: 6-month follow-up
Cervical cytology testing at 9-month follow-up
Timeframe: 9-month follow-up
Cervical cytology testing at 12-month follow-up
Timeframe: 12-month follow-up
16SrRNA sequencing of the vaginal secretions at baseline
Timeframe: Baseline
16SrRNA sequencing of the vaginal secretions at 3-month follow-up
Timeframe: 3-month follow-up
16SrRNA sequencing of the vaginal secretions at 6-month follow-up
Timeframe: 6-month follow-up
16SrRNA sequencing of the vaginal secretions at 9-month follow-up
Timeframe: 9-month follow-up
16SrRNA sequencing of the vaginal secretions at 12-month follow-up
Timeframe: 12-month follow-up
Human Papillomavirus (HPV) genotyping tests at baseline
Timeframe: Baseline
Human Papillomavirus (HPV) genotyping tests at 3-month follow-up
Timeframe: 3-month follow-up
Human Papillomavirus (HPV) genotyping tests at 9-month follow-up
Timeframe: 9-month follow-up